Study of VIB7734 for the Treatment of Moderate to Severely Active SLE (RECAST SLE)

  • STATUS
    Not Recruiting
  • End date
    Oct 1, 2023
  • participants needed
    195
  • sponsor
    Viela Bio (acquired by Horizon Therapeutics)
Updated on 19 August 2022

Summary

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants. The study duration will be 48 weeks, with a safety follow-up through week 56.There will be 3 parallel arms - 2 active treatment and 1 placebo.

Details
Condition Lupus Erythematosus, Systemic
Treatment Placebo, VIB7734
Clinical Study IdentifierNCT04925934
SponsorViela Bio (acquired by Horizon Therapeutics)
Last Modified on19 August 2022

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note